ecrin-mdr-crcClinical2015Malignant neoplasm of rectosigmoid junctionMalignant neoplasm of colonMalignant neoplasm of rectumMalignant Neoplasm Of RectumMalignant Neoplasm Of Rectosigmoid JunctionMalignant Neoplasm Of ColonObservationalhttps://newmdr.ecrin.org/Study/2431544Germany9ECRIN MDROtherfalseProspective non-interventional double study about gender specific differences in the treatment of colorectal cancer - Version: Treatment with oxaliplatin containing regimens LIV PharmaInterventions: Group 1: This non-interventional study is observing a patient population with histologically or cytologically diagnosed colorectal cancer, for which the treatment with oxaliplatin LIV Pharma is indicated according to SPC There are the special warnings and precautions for use in the SPC of Oxaliplatin LIV to be addressed. There are no specific procedures since this is an observation of practice routine. Primary outcome(s): - Effecacy under practical conditions. In detail: Was therapy with Irinotecan LIV Pharma discontinued within the planned therapy period and at what therapy success and what are the eventual discontinuation reasons collected at each visit and remission duration during the follow-up phase. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: treatment2015-09-152431544DRKS00009341U1111-1174-0832